ArticleFrontiers in pharmacology2025
Machine learning-based prediction model for lung ischemia-reperfusion injury: insights from disulfidptosis-related genes.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Disulfidptosis: Mechanisms, evidence boundaries, and translational opportunities.Redox biology · 2026Review
- Lung transplantation in 2025: a narrative review of progress, challenges, and the road ahead.Journal of thoracic disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to explore potential ischemia-reperfusion injury (IRI) predictive biomarkers related to disulfidptosis following lung transplantation. Methods: The study utilized datasets from the GEO database, specifically GSE145989 and GSE127003, which include samples of lung cold ischemia and reperfusion following transplantation. Differential expressed analysis and functional enrichment analysis were conducted to identify key genes associated with lung transplant IRI. Multiple machine learning algorithms (Generalized Linear Model, Support Vector Machine, and Random Forest) were applied for joint screening, leading to the construction of a predictive model. The CIBERSORT method was used to assess the infiltration levels of immune cells in lung tissue samples post-transplant. Finally, cell line and animal experiments were carried out to validate the effectiveness and applicability of the model. Results: A total of 14,592 hub differential-expressed genes were identified, showing significant changes in cold ischemia and reperfusion samples. Using the three machine learning algorithms for joint analysis, a predictive model composed of SLC7A11 and LRPPRC was constructed. This model demonstrated excellent predictive efficacy across multiple datasets, with area under the curve (AUC) values of 0.742 and 0.938, respectively. Additionally, significant differences in neutrophils and macrophages were observed in lung transplant cold ischemia and reperfusion samples. Based on the differential genes associated with disulfidptosis and utilizing the CMap database, we identified two potential drugs targeting IRI: olanzapine and vortioxetine. Ultimately, cell line and animal experiments validated the predictive model's reliability and potential clinical value, revealing that disulfidptosis presents in IRI, and high SLC7A11 expression promotes IRI, while low LRPPRC expression contributes to its occurrence. Conclusion: SLC7A11 and LRPPRC can serve as predictive biomarkers for IRI following lung transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.